Avedro, Inc. is developing Keraflex™, an incision-less vision correction procedure enabled by advanced proprietary technology.
Keraflex, which uses focused energy to gently reshape the front surface of the cornea, will represent a unique offering in vision correction as it does not require the creation of a flap in the cornea nor does it involve the removal of any corneal tissue. This well differentiated procedure profile is likely to be particularly appealing to low-to-moderate myopes seeking an alternative to glasses and contact lenses.
The technology behind Keraflex has benefited from 15 years of development at Dartmouth’s Thayer School of Engineering and at the Dartmouth Medical Center. Proof of concept has been well established in various in vitro and in vivo models. Clinical trials are slated to commence shortly and will be followed by product launch in Europe.
Avedro is led by David Muller, PhD, the founder, COB and CEO of Summit Technology, Inc., the first company to receive FDA approval for laser vision correction, with John Marshall, PhD, of the Rayne Institute at St. Thomas’ Hospital in London, acting as lead scientific adviser.
In February 2008, Avedro closed $8 million in Series A-1 funding. The principal investors were De Novo Ventures, Prism VentureWorks, and Borealis Ventures
|
